Gene Therapy to Target Mesothelin for Oncology is under clinical development by Shenzhen BinDeBio and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II drugs for Gastric Cancer have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Gene Therapy to Target Mesothelin for Oncology’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Gene Therapy to Target Mesothelin for Oncology overview

Gene Therapy is under development for the treatment of metastatic pancreatic cancer, glioblastoma, liver cancer, gastric cancer and esophageal cancer. It is administered by intravenous route. The therapeutic candidate comprises autologous T cells engineered to express chimeric antigen receptor (CAR) consisting of an anti-mesothelin single chain variable fragment (scFv) and fused to co-stimulatory domain 4-1BB and TCR zeta.

For a complete picture of Gene Therapy to Target Mesothelin for Oncology’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.